Bright Minds Biosciences Inc. (DRUG.CN) Research

Bright Minds Biosciences Inc. is an early-stage biopharmaceutical firm dedicated to creating serotonin (5-HT) based therapies. The company aims to enhance the well-being of individuals afflicted by debilitating and severe medical conditions. Its pipeline features a range of selective 5-HT receptor agonists, specifically targeting 5-HT2C, 5-HT2A, and combined 5-HT2C/A receptors. These compounds are being investigated for their potential in treating epilepsy, various pain conditions, and neuropsychiatric disorders. Bright Minds Biosciences has established partnerships with the National Institutes of Health for epilepsy research, the University of Texas Medical Branch to address impulse control issues like binge eating, and the Medical College of Wisconsin. Founded in 2019, the company operates from its headquarters in Vancouver, Canada.

Market snapshot

Symbol
DRUG.CN
Price
$87.58
Day change
+3.38%
Market cap
$679.8M
P/E ratio
-25.83x
52-week range
33.01-170
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Cresco Labs Inc. (CL.CN)
  • Spectral Medical Inc. (EDT.TO)
  • Eupraxia Pharmaceuticals Inc. (EPRX.TO)
  • Fennec Pharmaceuticals Inc. (FRX.TO)
  • Knight Therapeutics Inc. (GUD.TO)
  • High Tide Inc. (HITI.V)
  • Kneat.com, Inc. (KSI.TO)
  • NervGen Pharma Corp. (NGEN.V)

Open Bright Minds Biosciences Inc. (DRUG.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.